Stimulation by hCRF of C-peptide release in type 2 diabetics during concomitant opioid receptor blockade.
Administration of synthetic human corticotropin-releasing factor (hCRF, 2 micrograms/kg body weight) during simultaneous application of the opioid antagonist naloxone (1.6 mg i.v. bolus, followed by an infusion at a rate of 1.2 mg/h) produced a significant increase in plasma C-peptide levels of six male Type 2 diabetic patients which even exceeded the postprandial values. This stimulatory effect of hCRF/naloxone on plasma C-peptide was less pronounced in six healthy men. hCRF alone did not provoke any reaction of plasma C-peptide in either group. The possibility of a paracrine, CRF-dependent mechanism in pancreatic islets which somehow involves inhibitory opioid receptors is preferentially discussed. Such a mechanism may underlie the stimulatory action of hCRF/naloxone on B cells and would explain the absent reaction of peripheral venous plasma C-peptide to hCRF alone as well as the amplifying effect of simultaneous opioid receptor blockade.
Ehrenreich
H
H
Medizinische Poliklinik, Universität München.
Kolmar
C
C
Pittius
C
C
Goebel
F D
FD
D001786:Blood Glucose / Q000378:metabolism; D002096:C-Peptide / Q000097:blood*; D003346:Corticotropin-Releasing Hormone / Q000494:pharmacology*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D004435:Eating; D006801:Humans; D009270:Naloxone / Q000494:pharmacology*; D011957:Receptors, Opioid / Q000187:drug effects*
D001786:Blood Glucose; D002096:C-Peptide; D011957:Receptors, Opioid; D009270:Naloxone; D003346:Corticotropin-Releasing Hormone